Latest news with #DCAI
Yahoo
5 days ago
- Health
- Yahoo
Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
Orbis begins using Gefion, Denmark's first AI supercomputer Composed of 1,528 NVIDIA H100 Tensor Core GPUs, system is optimized for large-scale, AI-driven projects Enables significant expansion of macrocycle chemical space exploration by Orbis' nGen platform New AI/ML capacity will leverage large proprietary datasets and generative AI to design novel orally available macrocycle alternatives to existing biologics COPENHAGEN, Denmark, June 03, 2025--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark's first AI supercomputer, Gefion, which is owned and operated by DCAI. Gefion will allow the company to accelerate its mission of developing oral alternatives to widely used biologics and targeting important intra- and extracellular proteins that are currently difficult or impossible to drug with orally bioavailable compounds. Orbis is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. The company develops compounds known as nCycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features. "Our advanced nGen platform helps us quickly create large numbers of custom-designed macrocycles with unique properties and broad medical applicability," said Orbis CEO Morten Graugaard. "By combining this platform with Gefion's computing power, we can extend beyond the nearly 140 billion compounds in our existing libraries to design entirely new collections of these molecules. This means we can explore an even broader range of chemical possibilities and more fully unlock the potential of macrocycles to improve healthcare." "Orbis' nGen platform, which has already been used to design, synthesize and test more than 700,000 individual nCycles, is an ideal application for Gefion's capabilities," said Orbis Medicines Board Chair Mikael Dolsten, M.D., Ph.D. "Combining the power of this supercomputer with our in-house target nCycle data collection, generative AI, and nCycle synthesis capabilities will accelerate the development of orally available macrocycles that have the potential to disrupt the current biologics market and provide new treatment options for patients." "Gefion is designed to deliver AI innovation at scale through immense computing power applied to the most challenging problems," said Dr. Nadia Carlsten, CEO of DCAI. "As a biomedical start-up with its own internal AI technology applied to drug design and the ability to generate vast data sets, Orbis is an ideal partner to demonstrate what Gefion can unlock when matched with specialist expertise." DCAI's Gefion supercomputer contains 1,528 NVIDIA GPUs and is optimized for large-scale AI-driven projects. Gefion enables innovators to utilize advanced computation to accelerate discovery in various fields, including biotechnology and drug discovery. Gefion has previously been used by researchers, start-ups, and large enterprises to develop new AI models and perform simulations in weather modeling, quantum computing, and business automation. About Orbis Medicines Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its nGen platform systematically delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis' pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis' work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: About nGen nGen is Orbis Medicines' technology platform for generating nCycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a "lab in a loop" system starting with hit finding libraries of 100 billion compounds and target specific libraries designed by generative AI. The highly automated chemistry-based nGen platform can synthesize and screen up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning and generative AI, creates an industry-leading platform that de-risks and accelerates development. About DCAI The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark's flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI's mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024. View source version on Contacts Media: Matt CrensonTen Bridge Communications(917) 640-7930mcrenson@ General enquiries for DCAI & Gefion hello@ (+45) 35 27 66 00 Sign in to access your portfolio
Business Wire
5 days ago
- Business
- Business Wire
Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark's first AI supercomputer, Gefion, which is owned and operated by DCAI. Gefion will allow the company to accelerate its mission of developing oral alternatives to widely used biologics and targeting important intra- and extracellular proteins that are currently difficult or impossible to drug with orally bioavailable compounds. Orbis is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. The company develops compounds known as n Cycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features. 'Our advanced n Gen platform helps us quickly create large numbers of custom-designed macrocycles with unique properties and broad medical applicability,' said Orbis CEO Morten Graugaard. 'By combining this platform with Gefion's computing power, we can extend beyond the nearly 140 billion compounds in our existing libraries to design entirely new collections of these molecules. This means we can explore an even broader range of chemical possibilities and more fully unlock the potential of macrocycles to improve healthcare.' 'Orbis' n Gen platform, which has already been used to design, synthesize and test more than 700,000 individual n Cycles, is an ideal application for Gefion's capabilities,' said Orbis Medicines Board Chair Mikael Dolsten, M.D., Ph.D. 'Combining the power of this supercomputer with our in-house target n Cycle data collection, generative AI, and n Cycle synthesis capabilities will accelerate the development of orally available macrocycles that have the potential to disrupt the current biologics market and provide new treatment options for patients.' 'Gefion is designed to deliver AI innovation at scale through immense computing power applied to the most challenging problems,' said Dr. Nadia Carlsten, CEO of DCAI. 'As a biomedical start-up with its own internal AI technology applied to drug design and the ability to generate vast data sets, Orbis is an ideal partner to demonstrate what Gefion can unlock when matched with specialist expertise.' DCAI's Gefion supercomputer contains 1,528 NVIDIA GPUs and is optimized for large-scale AI-driven projects. Gefion enables innovators to utilize advanced computation to accelerate discovery in various fields, including biotechnology and drug discovery. Gefion has previously been used by researchers, start-ups, and large enterprises to develop new AI models and perform simulations in weather modeling, quantum computing, and business automation. About Orbis Medicines Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its n Gen platform systematically delivers macrocycle candidates, termed n Cycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis' pipeline is initially focused on n Cycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis' work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: About n Gen n Gen is Orbis Medicines' technology platform for generating n Cycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a 'lab in a loop' system starting with hit finding libraries of 100 billion compounds and target specific libraries designed by generative AI. The highly automated chemistry-based n Gen platform can synthesize and screen up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning and generative AI, creates an industry-leading platform that de-risks and accelerates development. About DCAI The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark's flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI's mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024.
Yahoo
13-05-2025
- Business
- Yahoo
AI Supercomputer Gefion welcomes new customer Kvantify to Simulate Quantum Computers
COPENHAGEN, Denmark, May 13, 2025 /PRNewswire/ -- Danish Center for AI Innovation (DCAI) is pleased to announce that Kvantify, a Danish pioneer in quantum software for chemistry and drug discovery, will be using the AI supercomputer Gefion to simulate quantum computers at scale. While Gefion has previously supported quantum computing research initiatives, Kvantify is the first dedicated quantum software company to harness its capabilities. Kvantify is leveraging Gefion's GPU-accelerated infrastructure to run and scale its novel simulator optimized for chemistry problems. Kvantify's software includes proprietary algorithms which are essential for accurately modeling molecular systems and reaction pathways relevant to drug design and enzyme engineering. "Gefion provides exaflop class performance for AI, and its specialized hardware happens to also be perfectly suited for simulated quantum computing," said Casper Kirkegaard, Head of Engineering at Kvantify. "This allows us to simulate future quantum computers today, which we are currently looking to utilize for industry relevant molecules such as penicillin using hundreds of qubits" The collaboration also highlights Gefion's broader role as an infrastructure backbone for emerging quantum R&D. As quantum technologies continue to evolve, Gefion provides the computational power needed to simulate, test, and refine quantum algorithms, enabling researchers to accelerate breakthroughs in a variety of fields—from materials science to optimization problems. "Gefion was built to push the boundaries of what's possible with AI infrastructure—and Kvantify is showing how that same AI hardware can deliver impact in quantum computing" said Nadia Carlsten, CEO of DCAI. "Their use case demonstrates how quantum software companies can meaningfully advance their work today using classical infrastructure designed for scale and specialization." "Simulating quantum computers is a fundamental step toward unlocking their real-world potential," said Hans Henrik Knudsen, CEO of Kvantify. "Gefion allows us to do this at a scale and speed we've never had before. This will directly accelerate the development of quantum algorithms and open new possibilities for future applications in science and technology." Kvantify's use of Gefion further underscores the AI supercomputer's versatility across domains beyond machine learning, including quantum simulation, molecular modeling, and next-generation HPC workflows. It also reflects a broader trend: the convergence of quantum research and classical infrastructure to solve today's most complex scientific problems. About KvantifyKvantify is a pioneering quantum software company based in Denmark. The company leverages quantum and high-performance computing to create revolutionizing solutions for complex scientific and industrial challenges. Kvantify's mission is to make quantum computing technology widely accessible, and a valuable tool for businesses worldwide. For more information, please visit ( About DCAI The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark's flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI's mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024. View original content: SOURCE Danish Centre for AI Innovation (DCAI) Sign in to access your portfolio
Yahoo
30-04-2025
- Business
- Yahoo
Intel's Struggles Continue, but Is a Turnaround Near?
Intel's (NASDAQ: INTC) first-quarter results came up flat, and investors sent shares of the struggling semiconductor company lower. Intel shares are down more than 40% over the past year. Revenue was flat for the quarter, coming in at $12.7 billion. Adjusted earnings per share (EPS) sank 28% to $0.13. The lackluster numbers easily surpassed the $0.01 in EPS and $12.3 billion in revenue in the analyst consensus compiled by LSEG, but Intel's guidance disappointed. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Let's take a closer look at Intel's quarterly results to see when a turnaround could be in store. Intel's flat revenue was the first time it didn't see a revenue decline since Q1 of last year. However, the company has been more stuck in the mud in regard to revenue growth than seeing any big declines. Intel's product revenue fell 3% to $11.8 billion. Its client computing group (CCG) product revenue fell 8% to $7.6 billion, while data center and AI (DCAI) product revenue rose 8% to $4.1 billion. The company said it saw better-than-expected sales of its Xeon chip, which is a CPU (central processing unit) designed for data centers and enterprise services. However, it said the growth was likely driven by customers increasing orders ahead of tariffs. Its foundry business, meanwhile, had revenue increase 7% to $4.7 billion. However, the segment continues to post large losses, with an operating loss of $2.3 billion in Q1. That was a slight improvement from its $2.4 billion loss a year ago. Revenue from Intel's other businesses, which include subsidiaries Altera and Mobileye, shot up 47% to $900 million. This segment also flipped from an operating loss of $170 million to a profit of $103 million. Segment Revenue Revenue Growth (YOY) Product $11.8 billion (3%) --CCG $7.6 billion (8%) --DCAI $4.1 billion 8% Foundry $4.7 billion 7% Other (subsidiaries) $900 million 47% Data source: Intel. YOY = year over year. Gross margins remain under pressure, falling by 410 basis points from 41% to 36.9%. Some of the gross-margin pressure stems from ramping up the foundry business, but Intel has also seen a lot of margin pressure in its CCG and DCAI businesses as well. The company produced $813 million in operating cash flow during the quarter, while spending $5.2 billion in capital expenditures (capex) as it continues to pour money into its foundry business. It ended the quarter with $50.2 billion in debt against $21.1 billion in cash and short-term investments. Looking ahead, it forecast Q2 revenue to range between $11.2 billion and $12.4 billion, well below analyst expectations for revenue of $12.8 billion. At the midpoint, that would be a year-over-year decline in revenue of about 8%. Due to its struggles, Intel is looking to significantly cut its operating expenses (opex). It plans to reduce opex to $17 billion this year and $16 billion in 2026. Excluding restructuring charges, opex was $22 billion in 2024, or $19.4 billion when excluding share-based compensation. Meanwhile, it reduced its capex budget by $2 billion to $18 billion, and it plans to monetize noncore assets. This will begin the process of improving its balance sheet. The simple answer to that question is no. None of this is a quick fix, and Intel won't be able to just cut its way to prosperity. On that front, it plans to refine its artificial intelligence (AI) strategy with the goal of developing full-stack AI solutions that improve accuracy, power efficiency, and security. That's a great goal to have, but Intel will have difficulty competing with a company like Nvidia, which is currently leaps and bounds ahead of it and has created a wide moat with the CUDA software platform. That said, I think there's value to be unlocked within Intel. Its core business, while not growing, has been fairly steady on the revenue front, and I would expect gross margins to eventually start to plateau. The company has a lot of physical assets, as it's poured money into its foundry business, building new fabrication plants in both the U.S. and Europe. It has spent over $200 billion in capex over the past two years, which is more than twice its market cap. As a result, Intel trades at a ratio of price to tangible book value (TBV) of just 1.2. TBV is the value of its physical assets minus any net debt, so basically, at current prices, investors are able to buy Intel at around the value of its assets. Investors will need to be patient, but I think there's enough value in Intel for its stock to eventually work. That means you might consider accumulating shares now, and on any further dips. Before you buy stock in Intel, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intel wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!* Now, it's worth noting Stock Advisor's total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intel and Nvidia. The Motley Fool recommends Mobileye Global and recommends the following options: short May 2025 $30 calls on Intel. The Motley Fool has a disclosure policy. Intel's Struggles Continue, but Is a Turnaround Near? was originally published by The Motley Fool Sign in to access your portfolio
Hi Dubai
28-04-2025
- Business
- Hi Dubai
Dubai AI Week Hackathon Showcases Future of Autonomous Innovation
Dubai's ambition to lead global AI innovation took center stage as the Dubai AI Week Hackathon: Agentic AI concluded the city's landmark tech event for 2025. Held at AREA 2071 in Emirates Towers Boulevard, the hackathon gathered developers, creatives, and innovators to design autonomous AI agents addressing real-world challenges in sectors like travel, logistics, finance, and real estate. Organised by the Dubai Centre for Artificial Intelligence (DCAI), part of the Dubai Future Foundation (DFF), and delivered with Hackmasters, the hackathon was a highlight of Dubai AI Week 2025, held under the patronage of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum. Over 170 participants formed 36 teams, first collaborating virtually from April 21 to 23, then advancing to two days of live hacking and demos at AREA 2071. Ten teams reached the final round, with the top three earning prizes for their innovative, autonomous solutions. Expert mentors and judges from organisations including DEWA, Microsoft, DeepOpinion AI, and Al Futtaim Group Real Estate supported the participants, providing technical expertise and strategic advice throughout the competition. Dubai AI Week 2025 featured 10 major events across the city, attracting over 10,000 attendees, 180 speakers, and 150 sessions. Strategic gatherings like the AI Retreat, Dubai Assembly for AI, and the Global Prompt Engineering Championship reflected the city's drive to position itself as a global hub for responsible and impactful AI innovation. News Source: Emirates News Agency
